openPR Logo
Press release

Neurofibromatosis Market Dynamics Indicate Upward Trajectory Through 2032, Reports DelveInsight

08-16-2025 05:31 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Neurofibromatosis Market Dynamics Indicate Upward Trajectory

DelveInsight's "Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Neurofibromatosis Market Report:
• The Neurofibromatosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
• In February 2025, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on rare diseases and cancer, announced the online publication of pivotal Phase 2b ReNeu trial data in the Journal of Clinical Oncology (JCO). The study assessed mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). These results, from the multi-center, single-arm ReNeu trial, were previously presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
• In November 2024, Alexion, AstraZeneca Rare Disease, and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, reported positive topline results from the Phase 3 KOMET trial-the largest global, randomized, double-blind, placebo-controlled multicenter study in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The results showed that KOSELUGO, an oral and selective MEK inhibitor, demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR), the study's primary endpoint, compared to placebo.
• According to secondary research, Neurofibromatosis Type 1 accounts for approximately 96% of all neurofibromatosis cases, with a prevalence of about 1 in 3,000 births. It affects all genders and races equally, with 50% of cases resulting from spontaneous mutations and the other half from inherited mutations. Neurofibromatosis Type 2 represents around 3% of cases, with a prevalence ranging from 1 in 33,000 to 1 in 87,410 births.
• According to DelveInsight's estimates, in 2023, there were around 16,976 diagnosed prevalent cases of NF-2 across the 7MM, with approximately 10,592 cases reported in the US alone.
• In Italy, NF1 is the most common form of neurofibromatosis, with a prevalence of roughly 1 in 3,164 individuals. Data on NF2, however, remains limited, emphasizing the need for further research. In the UK, NF1 affects about 1 in 4,650 people, according to various studies. A systematic review reported a pooled prevalence of 1 in 3,164 across different populations, indicating that NF1 is a notable health concern both in the UK and worldwide.
• A German study estimated the prevalence of NF1 in 6-year-old children at approximately 1 in 2,996, with a 95% confidence interval ranging from 1 in 2,260 to 1 in 3,984.
• NF2 is relatively rare, with an estimated prevalence of around 1 in 25,000 people in the UK. This estimate comes from regional studies, including research in the North West of England that examined the incidence of vestibular schwannomas linked to NF2.
• A 2023 study in Japan classified NF1 as a rare disease, yet noted it is among the most common genetic disorders globally. Its prevalence is estimated at 1 in 3,000 people in Japan and ranges from 1 in 3,000 to 1 in 6,000 worldwide. NF1 patients reportedly have a 10-15-year shorter life expectancy compared to the general population.
• Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, Merck Sharp & Dohme LLC, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, Array BioPharma, Recursion Pharmaceuticals, and others
• Key Neurofibromatosis Therapies: FCN-159, NFX-179 Gel, HL-085, RAD001:Everolimus:, Selumetinib granule formulation, Mirdametinib (PD-0325901), NFX-179, Selumetinib, Trametinib, Binimetinib, REC-2282, AZD2014, and others
• The Neurofibromatosis epidemiology based on type-specific cases analyzed that Prevalent Cases of Neurofibromatosis is highest for NF1
• The Neurofibromatosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis pipeline products will significantly revolutionize the Neurofibromatosis market dynamics.

Neurofibromatosis Overview
Neurofibromatosis is a genetic disorder characterized by the growth of noncancerous tumors on nerves throughout the body. It is caused by mutations in specific genes that affect nerve cell growth and development.

Get a Free sample for the Neurofibromatosis Market Report
https://www.delveinsight.com/report-store/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurofibromatosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neurofibromatosis Epidemiology Segmentation:
The Neurofibromatosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Neurofibromatosis
• Prevalent Cases of Neurofibromatosis by severity
• Gender-specific Prevalence of Neurofibromatosis
• Diagnosed Cases of Episodic and Chronic Neurofibromatosis

Download the report to understand which factors are driving Neurofibromatosis epidemiology trends @ Neurofibromatosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurofibromatosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis market or expected to get launched during the study period. The analysis covers Neurofibromatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurofibromatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurofibromatosis Therapies and Key Companies
• FCN-159: Fosun Pharmaceutical
• NFX-179 Gel: NFlection Therapeutics, Inc.
• HL-085: Shanghai Kechow Pharma
• RAD001:Everolimus: Novartis
• Selumetinib granule formulation: Merck Sharp & Dohme LLC
• Mirdametinib (PD-0325901): SpringWorks Therapeutics
• NFX-179: NFlection Therapeutics, Inc.
• Selumetinib: AstraZeneca
• Trametinib: Novartis
• Binimetinib: Array BioPharma
• REC-2282: Recursion Pharmaceuticals
• AZD2014: AstraZeneca

Discover more about therapies set to grab major Neurofibromatosis market share @ Neurofibromatosis Treatment Market
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Neurofibromatosis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, Merck Sharp & Dohme LLC, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, Array BioPharma, Recursion Pharmaceuticals, and others
• Key Neurofibromatosis Therapies: FCN-159, NFX-179 Gel, HL-085, RAD001:Everolimus:, Selumetinib granule formulation, Mirdametinib (PD-0325901), NFX-179, Selumetinib, Trametinib, Binimetinib, REC-2282, AZD2014, and others
• Neurofibromatosis Therapeutic Assessment: Neurofibromatosis current marketed and Neurofibromatosis emerging therapies
• Neurofibromatosis Market Dynamics: Neurofibromatosis market drivers and Neurofibromatosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neurofibromatosis Unmet Needs, KOL's views, Analyst's views, Neurofibromatosis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neurofibromatosis Market Dynamics Indicate Upward Trajectory Through 2032, Reports DelveInsight here

News-ID: 4146747 • Views:

More Releases from DelveInsight Business Research

DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) Across 15 Countries
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region. The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (PFO) Device Landscape Analysis Empowers Strategic Market Entry in the EU
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for Robust Growth at 6.35% CAGR through 2032, States DelveInsight
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers. The global
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market. The CD40 Pipeline report embraces in-depth commercial and

All 5 Releases


More Releases for Neurofibromatosis

Neurofibromatosis Type 2 (NF2) Market Massive Growth opportunity Ahead
Introduction Neurofibromatosis Type 2 (NF2) is a rare genetic disorder caused by mutations in the NF2 gene, leading to the development of benign tumours on the brain, spinal cord, and peripheral nerves. The hallmark of NF2 is bilateral vestibular schwannomas, which can cause hearing loss, balance issues, and neurological complications. While the condition is non-malignant, its progressive nature and impact on quality of life make it a serious healthcare challenge. Currently, there
Neurofibromatosis Type-1 Market Is Booming Worldwide - AstraZeneca, GlaxoSmithKl …
Neurofibromatosis Type-1 Market Insights The Neurofibromatosis Type-1 Market is projected to reach USD 2.4 billion by 2032, growing at a CAGR of 7.2% during the forecast period (2025-2032). Coherent Market Insights has published a new comprehensive analysis on the Neurofibromatosis Type-1 Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This report highlights essential metrics including market size, revenue forecasts, CAGR, adoption trends, and regulatory drivers. Backed by clinical evidence
Neurofibromatosis Treatment Market Size, Industry And Forecast To 2033
The new report published by The Business Research Company, titled Neurofibromatosis Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $11.41 billion in 2023
Neurofibromatosis Treatment Market Research Analysis, Application And Forecast T …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Neurofibromatosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $21.58 billion In 2028 At
Neurofibromatosis Treatment Market to Set Phenomenal Growth by 2023
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous
Neurofibromatosis Type I Market Trends and industry Analysis – 2024
Neurofibromatosis is caused due to a genetic mutation, resulting in the formation of tumors in various parts of a body, along nerve tissues, brain, and spinal cord. Among the three types of this disease, neurofibromatosis type I (NF1) is the most common. Often diagnosed in early adulthood or childhood, NF1 records to affect one behind each 2,000-2,500 people worldwide. Neurofibromatosis type I is characterized by severe skin pigmentation i.e. skin